Trial Profile
A PHASE 1, OPEN-LABEL, RANDOMIZED, FIXED-SEQUENCE, PARALLEL-COHORT STUDY TO ESTIMATE THE EFFECT OF FLUVOXAMINE OR FLUCONAZOLE, ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A SINGLE DOSE OF PF-04965842 IN HEALTHY SUBJECTS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs Abrocitinib (Primary) ; Fluconazole; Fluvoxamine
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 28 Feb 2022 Results of a pooled analysis (NCT03634345, NCT03637790 and NCT03937258 studies) assessed the effects of CYP inhibition, CYP induction, and OAT3 inhibition on the pharmacokinetics of abrocitinib, its metabolites, and active moiety published in the European Journal of Drug Metabolism and Pharmacokinetics
- 02 Jan 2019 Status changed from recruiting to completed.
- 18 Oct 2018 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.